BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 23895145)

  • 21. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
    Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
    J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
    Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
    Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
    Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
    Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.
    Verkooijen RB; Verburg FA; van Isselt JW; Lips CJ; Smit JW; Stokkel MP
    Eur J Endocrinol; 2008 Sep; 159(3):301-7. PubMed ID: 18567668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
    Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
    Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer.
    Wu S; Wang H
    Ann Endocrinol (Paris); 2013 Feb; 74(1):40-4. PubMed ID: 23337017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
    Díez JJ; Grande E; Iglesias P
    Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
    Súss SKA; Mesa CO; Carvalho GA; Miasaki FY; Chaves CP; Fuser DC; Corbo R; Momesso D; Bulzico DA; Graf H; Vaisman F
    Arch Endocrinol Metab; 2018; 62(2):149-156. PubMed ID: 29641738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
    Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
    Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term course in differentiated thyroid gland carcinoma].
    Rösler H; Birrer A; Lüscher D; Kinser J
    Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
    Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
    Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.